Empiric antibiotic selection and risk prediction of drug-resistant pathogens in community-onset pneumonia

Current Opinion in Infectious Diseases
Brandon J WebbNathan C Dean

Abstract

Empiric antibiotic selection in community-onset pneumonia is complicated by uncertainty regarding risk of drug-resistant pathogens (DRPs). The healthcare-associated pneumonia (HCAP) criteria have limited predictive value and lead to unnecessary antibiotic use. Better methods of predicting risk of DRP and selecting empiric antibiotics are needed. Here we give an update on risk factors for DRP, available risk prediction models, and treatment strategy in patients with pneumonia. Evidence supporting factors that contribute to risk of DRP has improved since the advent of HCAP. Many of these risk factors have been reproducibly identified in heterogeneous populations. Newer methods of predicting DRP based on these factors demonstrate better performance than HCAP. Recent innovations include the potential to discriminate between risk for methicillin-resistant Staphylococcus aureus and other DRP, and use of severity as a modifier of treatment threshold. However, there is wide variation in included predictor variables, and at proposed thresholds most scores still favor overtreatment. Until reliable molecular diagnostics are available, additional development and validation of decision support models integrating local resistance rates, esti...Continue Reading

References

May 15, 1980·The New England Journal of Medicine·S G Pauker, J P Kassirer
Sep 10, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ali A El SolhEileen Berbary
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Jun 28, 2005·Antimicrobial Agents and Chemotherapy·P Margreet G FiliusHubert P Endtz
Feb 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN American Thoracic Society
Jan 7, 2009·Annals of Internal Medicine·Mario VendittiUNKNOWN Study Group of the Italian Society of Internal Medicine
May 23, 2009·Journal of the American Geriatrics Society·Ali A El SolhAnil Patel
Feb 25, 2010·The Journal of Antimicrobial Chemotherapy·James D ChalmersJohn H Winter
Jan 25, 2011·The Lancet Infectious Diseases·Daniel H KettUNKNOWN Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators
Mar 15, 2011·BMC Infectious Diseases·Ji Ye JungYoung Ae Kang
Mar 26, 2011·The European Respiratory Journal·R T AttridgeE M Mortensen
May 19, 2011·The Journal of Antimicrobial Chemotherapy·Cynthia GrenierLouis Valiquette
Jun 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James D ChalmersAdam T Hill
Nov 1, 2011·Journal of Hospital Medicine : an Official Publication of the Society of Hospital Medicine·Karl J Madaras-KellyKevin L Sloan
Nov 24, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrew F ShorrMarin H Kollef
Nov 24, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stefano AlibertiFrancesco Blasi
Mar 2, 2012·Journal of Clinical Microbiology·Jay FischLona Mody
Aug 25, 2012·Respiratory Medicine·Brandon J WebbHolenarasipur R Vikram
Oct 17, 2012·Respirology : Official Journal of the Asian Pacific Society of Respirology·Stephanie Parks Taylor, Brice T Taylor
Apr 12, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S C ParkJ Y Jung
Jul 16, 2013·QJM : Monthly Journal of the Association of Physicians·H M MaT H Rainer
Jul 17, 2013·American Journal of Respiratory and Critical Care Medicine·Yuichiro ShindoYoshinori Hasegawa
Sep 4, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Takaya MaruyamaMichael S Niederman
Nov 26, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James D ChalmersSantiago Ewig
Nov 28, 2013·Antimicrobial Agents and Chemotherapy·Benjamin DangerfieldMaria Teresa Seville
Mar 14, 2014·The Lancet. Respiratory Medicine·Robert P DicksonGary B Huffnagle
Mar 26, 2014·Respirology : Official Journal of the Asian Pacific Society of Respirology·Hon Ming MaDavid S C Hui

❮ Previous
Next ❯

Citations

Dec 15, 2017·Respirology : Official Journal of the Asian Pacific Society of Respirology·Junya OkumuraUNKNOWN Central Japan Lung Study Group
Aug 6, 2017·Respirology : Official Journal of the Asian Pacific Society of Respirology·Yuichiro Shindo, Yoshinori Hasegawa
Nov 2, 2019·Annals of the American Thoracic Society·Andrew P Michelson, Marin H Kollef
Oct 2, 2017·BMC Infectious Diseases·Rosario MenéndezAntoni Torres

❮ Previous
Next ❯

Software Mentioned

Aliberti

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Journal of Hospital Medicine : an Official Publication of the Society of Hospital Medicine
Karl J Madaras-KellyKevin L Sloan
Revista de calidad asistencial : organo de la Sociedad Española de Calidad Asistencial
T García-LozanoA Egido-González
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Giovanna Fabio, Maria Carrabba
© 2022 Meta ULC. All rights reserved